Site Editor

Leo I. Gordon, MD, FACP

Advertisement
Advertisement

ASH 2022: Glofitamab Monotherapy for Resistant Mantle Cell Lymphoma

By: Kayci Reyer
Posted: Tuesday, December 13, 2022

According to a retrospective cohort study, presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 74), single-agent treatment with the monoclonal antibody glofitamab may benefit heavily pretreated patients with relapsed or refractory mantle cell lymphoma. Tycel J. Phillips, MD, of the University of Michigan Medical School, Ann Arbor, and colleagues found that improvements in outcomes such as complete response may extend to patients who previously experienced disease progression after undergoing Bruton’s tyrosine kinase inhibitor therapy.

The study included 37 patients who had received glofitamab monotherapy with step-up dosing following obinutuzumab pretreatment. Patients received either 1,000 mg (n = 16) or 2,000 mg (n = 21) of obinutuzumab. More than half the patients were refractory to their first (n = 23) and/or their last previous therapy (n = 27).

At a median follow-up of 8 months, the overall response and complete response rates among all enrolled patients were 83.8% and 73.0%, respectively. By pretreatment cohort, respective overall response and complete response rates were 75.0% and 62.5% in the 1,000-mg group and 90.5% and 81.0% in the 2,000-mg group. Overall, the median time to response was 51 days, the median duration of response of 12.6 months, and the median duration of complete response was 10.0 months.

Adverse events did not lead to treatment discontinuation for any patient, according to the study authors. Cytokine-release syndrome (75%) and neutropenia (40.5%) were the most common adverse events. Although all cytokine-release syndrome events were manageable, patients in the 1,000-mg cohort experienced them more often (87.5% vs. 66.7%) and across a broader spectrum of grades (grades 1–4 vs. grades 1–3). Overall, 19 patients experienced neurologic adverse events, all of which were grade 2 or below except for a single grade 3 subdural hematoma. Ten patients died of causes unrelated to treatment.

Disclosure: For full disclosures of the study authors, visit ash.confex.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.